A

Arcellx Inc
NASDAQ:ACLX

Watchlist Manager
Arcellx Inc
NASDAQ:ACLX
Watchlist
Price: 90.44 USD 3.69% Market Closed
Market Cap: 4.9B USD
Have any thoughts about
Arcellx Inc?
Write Note

Arcellx Inc
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Arcellx Inc
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
A
Arcellx Inc
NASDAQ:ACLX
Cash from Investing Activities
-$154.5m
CAGR 3-Years
-458%
CAGR 5-Years
-217%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Investing Activities
-$19.7B
CAGR 3-Years
-121%
CAGR 5-Years
N/A
CAGR 10-Years
-20%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Investing Activities
-$4B
CAGR 3-Years
31%
CAGR 5-Years
6%
CAGR 10-Years
-13%
Amgen Inc
NASDAQ:AMGN
Cash from Investing Activities
-$27.7B
CAGR 3-Years
-304%
CAGR 5-Years
N/A
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Investing Activities
-$3.8B
CAGR 3-Years
N/A
CAGR 5-Years
-59%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Investing Activities
-$2.9B
CAGR 3-Years
8%
CAGR 5-Years
-7%
CAGR 10-Years
-17%
No Stocks Found

Arcellx Inc
Glance View

Market Cap
4.9B USD
Industry
Biotechnology

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 78 full-time employees. The company went IPO on 2022-02-04. The firm is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The firm is advancing its CART-ddBCMA product through its iMMagine Phase 2 pivotal trial in patients with relapsed or refractory (r/r) multiple myeloma (MM). The firm is also advancing ARC-SparX programs, ACLX-001 in r/r MM and ACLX-002 and ACLX-003 in r/r acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ARC-SparX are adaptable versions of ddCARs where the antigen-targeting region is located on a SparX protein that can be dosed separately from the ARC-T cells, its D-Domain based universal CAR-T cells that are designed to activate only when bound to a SparX protein that is bound to an antigen on a cell. The company is also exploring indications in solid tumors.

ACLX Intrinsic Value
43.51 USD
Overvaluation 52%
Intrinsic Value
Price
A

See Also

What is Arcellx Inc's Cash from Investing Activities?
Cash from Investing Activities
-154.5m USD

Based on the financial report for Dec 31, 2023, Arcellx Inc's Cash from Investing Activities amounts to -154.5m USD.

What is Arcellx Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-217%

Over the last year, the Cash from Investing Activities growth was -31%. The average annual Cash from Investing Activities growth rates for Arcellx Inc have been -458% over the past three years , -217% over the past five years .

Back to Top